Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Keiretsu Capital

Investor type Micro VC
Founders Matthew Le Merle Matthew Le Merle Nathan McDonald Randy Williams


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 87
Average round size
The average size of a deal this fund participated in
Portfolio companies 59
Rounds per year 5.80
Lead investments 1
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 8
Key employees 6
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Health Care
  • Biotechnology
  • Medical
  • Medical Device
  • Health Diagnostics

Keiretsu Capital appeared to be the VC, which was created in 2007. The main department of described VC is located in the Seattle. The venture was found in North America in United States.

The usual cause for the fund is to invest in rounds with 2-3 partakers. Despite the Keiretsu Capital, startups are often financed by Keiretsu Forum, Portland Seed Fund, Band of Angels. The meaningful sponsors for the fund in investment in the same round are Keiretsu Forum, Band of Angels, Sand Hill Angels. In the next rounds fund is usually obtained by Puget Sound Venture Club, Keiretsu Forum Northwest, Tech Coast Angels.

The fund has no exact preference in some founders of portfolio startups. When startup sums 4 or 5+ of the founder, the probability for it to get the investment is little. Among the most successful fund investment fields, there are SaaS, Internet. Among the most popular portfolio startups of the fund, we may highlight Transform, Inc., Alpin, Perkville. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. For fund there is a match between the location of its establishment and the land of its numerous investments - United States.

The usual things for fund are deals in the range of 1 - 5 millions dollars. The top activity for fund was in 2016. The fund is constantly included in 7-12 investment rounds annually. Considering the real fund results, this VC is 19 percentage points less often commits exit comparing to other organizations. When the investment is from Keiretsu Capital the average startup value is 5-10 millions dollars. This Keiretsu Capital works on 25 percentage points less the average amount of lead investments comparing to the other organizations. The higher amount of exits for fund were in 2019.

The fund was created by Matthew Le Merle, Matthew Le Merle, Nathan McDonald, Randy Williams. We also calculated 12 valuable employees in our database.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Keiretsu Capital:
Typical Co-investors
Keiretsu Capital is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Keiretsu Capital:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Advent France Biotechnology France, Ile-de-France, Paris
Allrise Capital -
Anhui University of Technology Anhui, China, Maanshan
Desert Sky Holdings California, Los Angeles, United States
Eldorado Gold Corp. British Columbia, Canada, Vancouver
Full Moon Investments Cary, North Carolina, United States
Inversiones Montferrat - China, Jiangsu, Nanjing
National Research Council of Canada Industrial Research Assistance Program Canada, Ontario, Ottawa
Radiant Haroti India, Jaipur, Rajasthan
Shanghai Side Weisi Chuangye Touzi Guanli Youxian Gongsi China, Shanghai
Stellar Development Foundation California, San Francisco, United States Beijing, China, Haidian
TGVest Capital Taipei, Taiwan
Toho Holdings Japan, Tokyo
Toyota Systems Aichi Prefecture, Japan, Nagoya
Wistron Corporation Taipei, Taiwan
ZHEXINIT China, Hangzhou, Zhejiang

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation


Health Care
Medical Device
$4M13 May 2021 Seattle, Washington, United States


Health Care
$4M11 Oct 2020 Raleigh, North Carolina, United States


Health Care
Medical Device
$14M08 Jul 2020 Washington, United States


Human Computer Interaction
Motion Capture
Virtual Reality
$12M20 Dec 2019 Seattle, Washington, United States

Embera NeuroTherapeutics

Drug Discovery
Medical Device
$4M19 Dec 2019 Massachusetts, United States


Green Building
Home and Garden
Innovation Management
Renewable Energy
$1M05 Aug 2019 Pennsylvania, United States

Astarte Medical

Health Care
Health Diagnostics
Predictive Analytics
$5M07 Mar 2019 Pennsylvania, United States

Virion Therapeutics

Health Care
$5M27 Sep 2018 Delaware, United States

Toma Biosciences

Health Care
$3M21 Jul 2018 Foster City, California, United States
Healionics raises $4.7M to commercialize artificial blood vessel tech

– Seattle-based medical technology company Healionics raised $4.7m funding.
– The round was led by Keiretsu Capital and joined by others.
– It will be used to complete a second human study and obtain FDA clearance.

Healionics Closes $4.7M Equity Financing

– Healionics is a clinical-stage company addressing the need for means of bloodstream access to perform dialysis in patients with kidney failure.
– The company announced the closing of a $4.7M equity financing led by Keiretsu Capital.
– The company also announced the conversion to equity of $5.2M in previously outstanding notes and interest.
– The new investment will be used to complete an ongoing human study and to obtain FDA market clearance.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Keiretsu Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: